On October 7, 2025, Aimed Alliance sent a follow-up letter to the U.S. Food and Drug Administration (FDA) regarding the Aimed Alliance’s March 2024 Citizen Petition to the FDA on third-party companies that partner with employer-sponsored health plans to require employees to import prescription drugs from outside the United States through alternative funding programs (AFPs). In August 2024, the FDA issued an interim response acknowledging the complexity of these issues.While Aimed Alliance appreciates the FDA’s thoughtful review and the Trump Administration’s commitment to lowering prescription drug costs for consumer, we remain concerned that AFPs may be mandating importation through non-FDA-approved pathways, which can expose patients to unsafe or counterfeit medications.
In response to these concerns, Aimed Alliance’s newest letter urges the FDA to establish clear requirements for these programs, including: (1) transparency about the legal authority for importation; (2) disclosure of the drug’s source and full chain of custody; (3) clear English labeling and usage instructions; (4) warnings about risks of non-FDA approved drugs; and (5) assurances that patients may refuse imported medications without penalty. Read the letter here.
Last Updated on October 7, 2025 by Aimed Alliance
